Fennec Pharmaceuticals Inc. (FENC) NASDAQ
9.98
+0.1(+1.01%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
9.98
+0.1(+1.01%)
Currency In USD
Address
68 TW Alexander Drive
Research Triangle Park, NC 27709
United States of America (the)
Phone
919 636 4530
Website
Sector
Healthcare
Industry
Biotechnology
Employees
32
First IPO Date
September 15, 2017
| Name | Title | Pay | Year Born |
| Jeffrey S. Hackman | Chief Executive Officer & Director | 632,176 | 1963 |
| Pierre S. Sayad | Chief Medical Officer | 464,081 | N/A |
| Robert C. Andrade | Chief Financial Officer | 552,646 | 1975 |
| Mark Gowland | Controller | 0 | N/A |
| Terry Evans | Chief Commercial Officer | 0 | N/A |
| Christiana Cioffi | Chief Strategy Officer | 0 | N/A |
| Lei Fang | President of Pharstat Inc | 0 | N/A |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.